LAKE FOREST, CA--(Marketwire - December 19, 2012) - TRIMEDYNE, INC. (OTCBB: TMED), today announced that Robert S. Cowles, III, M.D. has agreed to serve as Medical Director of Trimedyne. He will review Trimedyne's new technologies and advise Trimedyne on the design of the clinical trials to be conducted, subject to receipt of funding, by the seven (7) subsidiaries Trimedyne plans to organize (See Trimedyne's Press Release dated November 28, 2012).
Dr. Cowles is an accomplished surgeon and a highly respected Urologist who has lectured throughout the world on the use of lasers and other technologies in Urology. He was the first Urologist in the United States to use the first laser and side firing, fiber-optic device to treat benign prostate hyperplasia or "BPH," commonly referred to as an "enlarged prostate," which was developed by Trimedyne in the early 1990s. BPH affects 50 percent of men at age 55 and an increasing percentage of men at higher ages.
Dr. Cowles is Chairman of the Cowles Clinic, a 120 physician, multi-specialty clinic near Atlanta, GA. He has received four Professional Awards and Honors, nine Visiting Professorships and Teaching Appointments, holds nine Professional Offices, is a member of four Boards of Directors and is the author of many published papers.
Trimedyne manufactures proprietary Holmium lasers and patented and patent pending fiber optic laser devices to treat a variety of medical conditions in minimally invasive, procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "believe," "expect," "may," "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC Reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in the statements in such Reports, which Trimedyne has no obligation to update.